Dr. Tolaney received her undergraduate degree from Princeton University in 1998 and her medical degree from UC San Francisco in 2002. She subsequently completed her residency in Internal Medicine at Johns Hopkins University, and fellowships in hematology and medical oncology at Dana-Farber Cancer Institute. She obtained a Masters in Public Health from the Harvard School of Public Health in 2007. In 2008, she joined the staff of Dana-Farber Cancer Institute and Brigham and Women's Hospital, where she serves as Chief of the Division of Breast Oncology.  She is a breast medical oncologist whose research focuses on the development of novel therapies in the treatment of breast cancer.  She has been instrumental in developing several treatment approaches for breast cancer, including approaches focused on tailoring therapy for early stage HER2+ disease, use of CDK 4/6 inhibitors, antibody drug conjugates, and immunotherapy.

Dr. David Page is a medical oncologist and clinical investigator at the Providence Cancer Institute in Portland, Oregon. His area of expertise is in the field of breast cancer immunotherapy.

He completed a Bachelor’s of the Arts at the University of Chicago, a medical doctorate at Northwestern University, followed by internal medicine residency at Columbia University / New York Presbyterian and medical oncology fellowship at Memorial Sloan Kettering Cancer Center in New York City.

He has conducted and published outcomes of numerous investigator-initiated trials, including trials combining immune checkpoint blockade with chemotherapy, radiotherapy, and novel targeted/immune therapies in breast cancer, both in the curative and metastatic setting. He also has served on various immunotherapy-related committees, including the NCI Breast Immuno-oncology task force, the SITC Breast Immunotherapy expert panel, and the SITC multispectral immunofluorescence working group.